VALLEY RETINA INSTITUTE
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1995-01-01
- Employees
- -
- Market Cap
- -
Evaluation of Treatment of High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept injectioN
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2015-12-15
- Lead Sponsor
- Valley Retina Institute
- Target Recruit Count
- 30
- Registration Number
- NCT02630277
Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion
Phase 4
- Conditions
- Macular EdemaCentral Retinal Vein Occlusion
- Interventions
- First Posted Date
- 2013-04-10
- Last Posted Date
- 2015-12-14
- Lead Sponsor
- Valley Retina Institute
- Target Recruit Count
- 45
- Registration Number
- NCT01827722
- Locations
- 🇺🇸
Retina Associates, Lakeland, Florida, United States
🇺🇸Retina Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸Valley Retina Institute, PA, McAllen, Texas, United States
Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2013-07-16
- Lead Sponsor
- Valley Retina Institute
- Target Recruit Count
- 72
- Registration Number
- NCT01486238
- Locations
- 🇺🇸
Valley Retina Institute,PA, McAllen, Texas, United States
Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)
Phase 4
- Conditions
- Proliferative Diabetic Retinopathy
- Interventions
- Drug: Macugen ® (pegaptanib sodium)
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2011-12-06
- Lead Sponsor
- Valley Retina Institute
- Target Recruit Count
- 30
- Registration Number
- NCT01486771
- Locations
- 🇺🇸
Valley Retina Insitute, PA, McAllen, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath